BACKGROUND: Tumor protein 53 (TP53) mutations are uncommon in adult patients with acute lymphoblastic leukemia (ALL) and predict a poor outcome. METHODS: TP53 mutation analysis was performed in 164 newly diagnosed adult patients with ALL using a combination of targeted amplicon-based next-generation sequencing and Sanger sequencing. RESULTS: TP53 mutations were detected in 25 patients (15%), with a median allelic frequency of 42.2% (range, 5.6%-93.8%). The majority of mutations were single-nucleotide variants of missense type and involved the DNA-binding domain. TP53-mutated (TP53mut ) ALL was found to be significantly associated with older age, lower median white blood cell and platelet counts, lower frequency of Philadelphia chromosome and a higher frequency of low hypodiploid karyotype compared with ALL with wild-type TP53 (TP53wt ). To evaluate the prognostic effect of TP53 mutations, the authors selected 146 patients with B-cell immunophenotype ALL (24 with TP53mut and 122 with TP53wt ) who were uniformly treated with frontline hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD)-based regimens; >90% of these individuals also received a monoclonal antibody. Over a median follow-up duration of 15 months, there was no significant difference in the median overall survival, event-free survival, and duration of complete remission noted between patients with TP53mut ALL and those with TP53wt ALL. CONCLUSIONS: Hyper-CVAD-based regimens appear to negate the poor prognostic impact of TP53 mutations in patients with adult B-cell immunophenotype ALL. Cancer 2017;123:3717-24.
BACKGROUND:Tumor protein 53 (TP53) mutations are uncommon in adult patients with acute lymphoblastic leukemia (ALL) and predict a poor outcome. METHODS:TP53 mutation analysis was performed in 164 newly diagnosed adult patients with ALL using a combination of targeted amplicon-based next-generation sequencing and Sanger sequencing. RESULTS:TP53 mutations were detected in 25 patients (15%), with a median allelic frequency of 42.2% (range, 5.6%-93.8%). The majority of mutations were single-nucleotide variants of missense type and involved the DNA-binding domain. TP53-mutated (TP53mut ) ALL was found to be significantly associated with older age, lower median white blood cell and platelet counts, lower frequency of Philadelphia chromosome and a higher frequency of low hypodiploid karyotype compared with ALL with wild-type TP53 (TP53wt ). To evaluate the prognostic effect of TP53 mutations, the authors selected 146 patients with B-cell immunophenotype ALL (24 with TP53mut and 122 with TP53wt ) who were uniformly treated with frontline hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD)-based regimens; >90% of these individuals also received a monoclonal antibody. Over a median follow-up duration of 15 months, there was no significant difference in the median overall survival, event-free survival, and duration of complete remission noted between patients with TP53mut ALL and those with TP53wt ALL. CONCLUSIONS:Hyper-CVAD-based regimens appear to negate the poor prognostic impact of TP53 mutations in patients with adult B-cell immunophenotype ALL. Cancer 2017;123:3717-24.
Authors: Ghayas C Issa; Hagop M Kantarjian; C Cameron Yin; Wei Qiao; Farhad Ravandi; Deborah Thomas; Nicholas J Short; Koji Sasaki; Guillermo Garcia-Manero; Tapan M Kadia; Jorge E Cortes; Naval Daver; Gautam Borthakur; Nitin Jain; Marina Konopleva; Issa Khouri; Partow Kebriaei; Richard E Champlin; Sherry Pierce; Susan M O'Brien; Elias Jabbour Journal: Cancer Date: 2016-10-03 Impact factor: 6.860
Authors: Farhad Ravandi; Jeffrey L Jorgensen; Susan M O'Brien; Elias Jabbour; Deborah A Thomas; Gautam Borthakur; Rebecca Garris; Xuelin Huang; Guillermo Garcia-Manero; Jan A Burger; Alessandra Ferrajoli; William Wierda; Tapan Kadia; Nitin Jain; Sa A Wang; Sergei Konoplev; Partow Kebriaei; Richard E Champlin; Deborah McCue; Zeev Estrov; Jorge E Cortes; Hagop M Kantarjian Journal: Br J Haematol Date: 2015-10-22 Impact factor: 6.998
Authors: Rashmi Kanagal-Shamanna; Rajyalakshmi Luthra; Cameron C Yin; Keyur P Patel; Koichi Takahashi; Xinyan Lu; John Lee; Chong Zhao; Francesco Stingo; Zhuang Zuo; Mark J Routbort; Rajesh R Singh; Patricia Fox; Farhad Ravandi; Guillermo Garcia-Manero; L Jeffrey Medeiros; Carlos E Bueso-Ramos Journal: Oncotarget Date: 2016-03-22
Authors: Sankaranarayanan Kannan; Marisa J L Aitken; Shelley M Herbrich; Leonard S Golfman; Mandy G Hall; Duncan H Mak; Jared K Burks; Guangchun Song; Marina Konopleva; Charles G Mullighan; Joya Chandra; Patrick A Zweidler-McKay Journal: Mol Cancer Ther Date: 2019-06-21 Impact factor: 6.261
Authors: Y Y Du; K K Lyu; M M Xu; W Q Yao; H Z Kang; Y Han; X W Tang; X Ma; X J Wu; X F He; D P Wu; Y J Liu Journal: Zhonghua Xue Ye Xue Za Zhi Date: 2021-05-14